vs

Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Simply Good Foods Co (SMPL). Click either name above to swap in a different company.

Simply Good Foods Co is the larger business by last-quarter revenue ($340.2M vs $196.9M, roughly 1.7× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -0.3%). Simply Good Foods Co produced more free cash flow last quarter ($48.0M vs $43.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 3.0%).

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

Whole Foods Market, Inc. is an American multinational supermarket chain headquartered in Austin, Texas, owned wholly by Amazon, and which generally sells whole food products free from hydrogenated fats and artificial colors, flavors, and preservatives. A USDA Certified Organic grocer in the United States, the chain is popularly known for its organic selections.

PCRX vs SMPL — Head-to-Head

Bigger by revenue
SMPL
SMPL
1.7× larger
SMPL
$340.2M
$196.9M
PCRX
Growing faster (revenue YoY)
PCRX
PCRX
+5.5% gap
PCRX
5.1%
-0.3%
SMPL
More free cash flow
SMPL
SMPL
$4.5M more FCF
SMPL
$48.0M
$43.5M
PCRX
Faster 2-yr revenue CAGR
PCRX
PCRX
Annualised
PCRX
8.5%
3.0%
SMPL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PCRX
PCRX
SMPL
SMPL
Revenue
$196.9M
$340.2M
Net Profit
$25.3M
Gross Margin
79.5%
32.3%
Operating Margin
1.2%
11.0%
Net Margin
7.4%
Revenue YoY
5.1%
-0.3%
Net Profit YoY
-33.7%
EPS (diluted)
$0.05
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCRX
PCRX
SMPL
SMPL
Q4 25
$196.9M
$340.2M
Q3 25
$179.5M
Q2 25
$181.1M
$381.0M
Q1 25
$168.9M
Q4 24
$187.3M
$341.3M
Q3 24
$168.6M
$375.7M
Q2 24
$178.0M
$334.8M
Q1 24
$167.1M
$312.2M
Net Profit
PCRX
PCRX
SMPL
SMPL
Q4 25
$25.3M
Q3 25
$5.4M
Q2 25
$-4.8M
$41.1M
Q1 25
$4.8M
Q4 24
$38.1M
Q3 24
$-143.5M
$29.3M
Q2 24
$18.9M
$41.3M
Q1 24
$9.0M
$33.1M
Gross Margin
PCRX
PCRX
SMPL
SMPL
Q4 25
79.5%
32.3%
Q3 25
80.9%
Q2 25
77.4%
36.4%
Q1 25
79.7%
Q4 24
78.7%
38.2%
Q3 24
76.9%
38.8%
Q2 24
75.1%
39.9%
Q1 24
71.6%
37.4%
Operating Margin
PCRX
PCRX
SMPL
SMPL
Q4 25
1.2%
11.0%
Q3 25
3.5%
Q2 25
4.7%
15.6%
Q1 25
1.2%
Q4 24
13.2%
16.0%
Q3 24
-82.8%
12.7%
Q2 24
15.9%
17.6%
Q1 24
7.9%
15.4%
Net Margin
PCRX
PCRX
SMPL
SMPL
Q4 25
7.4%
Q3 25
3.0%
Q2 25
-2.7%
10.8%
Q1 25
2.8%
Q4 24
11.2%
Q3 24
-85.1%
7.8%
Q2 24
10.6%
12.3%
Q1 24
5.4%
10.6%
EPS (diluted)
PCRX
PCRX
SMPL
SMPL
Q4 25
$0.05
$0.26
Q3 25
$0.12
Q2 25
$-0.11
$0.40
Q1 25
$0.10
Q4 24
$0.38
$0.38
Q3 24
$-3.11
$0.29
Q2 24
$0.39
$0.41
Q1 24
$0.19
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCRX
PCRX
SMPL
SMPL
Cash + ST InvestmentsLiquidity on hand
$238.4M
$194.1M
Total DebtLower is stronger
$372.2M
Stockholders' EquityBook value
$693.1M
$1.7B
Total Assets
$1.3B
$2.5B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCRX
PCRX
SMPL
SMPL
Q4 25
$238.4M
$194.1M
Q3 25
$246.3M
Q2 25
$445.9M
$98.0M
Q1 25
$493.6M
Q4 24
$484.6M
$121.8M
Q3 24
$453.8M
$132.5M
Q2 24
$404.2M
$208.7M
Q1 24
$325.9M
$135.9M
Total Debt
PCRX
PCRX
SMPL
SMPL
Q4 25
$372.2M
Q3 25
$376.7M
Q2 25
$580.5M
Q1 25
$583.4M
Q4 24
$585.3M
Q3 24
$397.5M
Q2 24
$237.7M
Q1 24
$237.7M
Stockholders' Equity
PCRX
PCRX
SMPL
SMPL
Q4 25
$693.1M
$1.7B
Q3 25
$727.2M
Q2 25
$757.8M
$1.8B
Q1 25
$798.5M
Q4 24
$778.3M
$1.8B
Q3 24
$749.6M
$1.7B
Q2 24
$879.3M
$1.7B
Q1 24
$892.2M
$1.6B
Total Assets
PCRX
PCRX
SMPL
SMPL
Q4 25
$1.3B
$2.5B
Q3 25
$1.3B
Q2 25
$1.5B
$2.4B
Q1 25
$1.6B
Q4 24
$1.6B
$2.4B
Q3 24
$1.5B
$2.4B
Q2 24
$1.6B
$2.2B
Q1 24
$1.6B
$2.1B
Debt / Equity
PCRX
PCRX
SMPL
SMPL
Q4 25
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
0.23×
Q2 24
0.14×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCRX
PCRX
SMPL
SMPL
Operating Cash FlowLast quarter
$43.7M
$50.1M
Free Cash FlowOCF − Capex
$43.5M
$48.0M
FCF MarginFCF / Revenue
22.1%
14.1%
Capex IntensityCapex / Revenue
0.1%
0.6%
Cash ConversionOCF / Net Profit
1.98×
TTM Free Cash FlowTrailing 4 quarters
$136.7M
$223.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCRX
PCRX
SMPL
SMPL
Q4 25
$43.7M
$50.1M
Q3 25
$60.8M
Q2 25
$12.0M
$101.1M
Q1 25
$35.5M
Q4 24
$33.1M
$32.0M
Q3 24
$53.9M
$48.9M
Q2 24
$53.2M
$72.8M
Q1 24
$49.1M
$46.5M
Free Cash Flow
PCRX
PCRX
SMPL
SMPL
Q4 25
$43.5M
$48.0M
Q3 25
$57.0M
Q2 25
$9.3M
$98.9M
Q1 25
$26.9M
Q4 24
$31.0M
$31.7M
Q3 24
$49.8M
$45.0M
Q2 24
$51.6M
$72.0M
Q1 24
$46.3M
$46.1M
FCF Margin
PCRX
PCRX
SMPL
SMPL
Q4 25
22.1%
14.1%
Q3 25
31.7%
Q2 25
5.1%
25.9%
Q1 25
15.9%
Q4 24
16.6%
9.3%
Q3 24
29.6%
12.0%
Q2 24
29.0%
21.5%
Q1 24
27.7%
14.8%
Capex Intensity
PCRX
PCRX
SMPL
SMPL
Q4 25
0.1%
0.6%
Q3 25
2.2%
Q2 25
1.5%
0.6%
Q1 25
5.1%
Q4 24
1.1%
0.1%
Q3 24
2.4%
1.0%
Q2 24
0.9%
0.2%
Q1 24
1.7%
0.1%
Cash Conversion
PCRX
PCRX
SMPL
SMPL
Q4 25
1.98×
Q3 25
11.20×
Q2 25
2.46×
Q1 25
7.37×
Q4 24
0.84×
Q3 24
1.67×
Q2 24
2.82×
1.76×
Q1 24
5.47×
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

SMPL
SMPL

Quest$211.4M62%
Atkins Domain$79.7M23%
OWYN$28.1M8%
Other$20.9M6%

Related Comparisons